一分钟看懂
这是一项关于Haematological Malignancy的II 期 / III 期研究，登记的药物或干预包括Alectinib；Atezolizumab；Entrectinib；Trastuzumab in combination with pertuzumab；Vemurafenib in combination with cobimetinib；Capmatinib；Dabrafe，当前状态为招募中。登记地点显示中国Belfast、Birmingham、Bristol、Cambridge等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Alectinib；Atezolizumab；Entrectinib；Trastuzumab in combination with pertuzumab；Vemurafenib in combination with cobimetinib；Capmatinib；Dabrafenib in combination with trametinib · II 期 / III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Belfast City Hospital · Belfast
- University Hospital Birmingham · Birmingham
- Birmingham Children's Hospital · Birmingham
- Bristol Royal Hospital for Children · Bristol
- Bristol Haematology and Oncology Centre · Bristol
- Addenbrooke's Hospital · Cambridge
- Velindre Cancer Centre · Cardiff
- Cardiff Children's Hospital · Cardiff
- Western General Hospital · Edinburgh
- The Beatson Hospital · Glasgow
- Royal Hospital for Children Glasgow · Glasgow
- Leicester Royal Infirmary · Leicester
- Alder Hey Hospital · Liverpool
- University College London Hospital · London
- Guy's Hospital · London
- Great Ormond Street Hospital · London
- Royal Manchester Children's Hospital · Manchester
- The Christie Hospital · Manchester
- Clatterbridge Cancer Centre · Metropolitan Borough of Wirral
- Great North Children's Hospital · Newcastle
- Freeman Hospital · Newcastle
- Churchill Hospital · Oxford
- John Radcliffe Hospital · Oxford
- Weston Park Hospital · Sheffield
- Sheffield's Children's Hospital · Sheffield
- Southampton General Hospital · Southampton
- The Royal Marsden Hospital · Sutton
公开的入选条件
- 1. Any patient (adult patients or children and TYA as defined in each treatment arm appendix) with histologically proven locally advanced or metastatic cancer (solid tumour or haematological malignancy) who has:
- 1. exhausted (or declined) standard-of-care treatment options.
- 2. or for whom no effective standard treatment is available.
- 3. and whose disease has progressed or is refractory. Exceptional circumstances may apply as described in the protocol.
- 2. Diagnosis of a rare cancer harbouring an actionable genomic alteration, or common cancer types with rare actionable genomic alterations, that has been identified using a validated next-generation sequencing method and for which there is a relevant open trea
- 3. Life expectancy of at least three months.
- 4. Patients are able to provide written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up. For patients under 16 years old, the parent or legal guardian will be asked to provide written informed consent and the pat
- 5. Patients with objectively evaluable or measurable disease, according to an assessment method appropriate for their cancer type.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05722886；登记信息更新于 2026-07-01。